Hunter Smith has been our Chief Financial Officer since August 2017, and served as our interim Chief Executive Officer from March to July 2020. Since joining Rhythm, Hunter led the company in an initial public offering that netted the Company $125 million, as well as two follow-on public offerings that netted approximately $346 million. As a member of the management team, Hunter has played a critical role in charting Rhythm’s corporate strategy and enabling its growth and development. He has over 25 years’ experience in global finance and management roles across multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. He joined Rhythm from Celgene Corporation, where he served as Vice President, Finance and Chief Financial Officer of the Company’s Inflammation and Immunology Business Unit. In this role, Hunter provided finance leadership for the global launch of Otezla®, co-led the integration of Receptos, Inc. following its acquisition by Celgene, and led global business planning and analysis for operations in over 16 countries. Before joining Celgene, Hunter worked for fourteen years in roles of increasing responsibility at Bunge Limited, including Director of Investor Relations, Chief Financial Officer–Asia, Chief Risk Officer, Corporate Treasurer, and Chief Financial Officer of Bunge’s Sugar and Bioenergy Segment. He holds an MBA in Finance from NYU’s Stern School of Business and a BA in History, with honors, from Northwestern University. Hunter served as an Independent Director of Genessee & Wyoming Inc. and as a member of the Compensation and Governance Committees, from 2015 until its acquisition by Brookfield Infrastructure Partners in December 2019.
We are taking a scientifically rigorous and truly cross-functional approach to identify a solution for a dire unmet need that no one else has taken on.